Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies [Phase 2]
This update reports a Phase 2 trial of loncastuximab tesirine for relapsed or refractory B-cell malignancies that is currently recruiting, i…
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies [Phase 1]
Phase 1 clinical trial update of acalabrutinib in Japanese adults with advanced B-cell malignancies, including relapsed/refractory CLL and m…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating pirtobrutinib as frontline therapy for elderly unfit/frail mantle cell lymphoma; trial status is not yet r…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of zanubrutinib and tafasitamab for Mantle Cell Lymphoma, currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment [Phase 2]
Phase 2 clinical trial evaluating chemotherapy combined with targeted therapy as first-line treatment for Mantle Cell Lymphoma, with MRD and…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 study update for IKS03 in advanced B-cell non-Hodgkin lymphomas is currently recruiting across multiple subtypes including diffuse l…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment [Phase 2]
A Phase 2 clinical trial evaluating orelabrutinib plus rituximab with optional autologous hematopoietic stem cell transplantation for mantle…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation [Phase 3]
A Phase 3 trial compares zanubrutinib plus rituximab against bendamustine plus rituximab in adults with previously untreated mantle cell lym…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This clinical trial update describes a study assessing vaccine responses in patients who previously received CAR-T therapy for multiple myel…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This entry provides an update on an ongoing Phase 1 trial of CD19-targeted CAR T-cells (CD19.20.22) for relapsed/refractory B-cell lymphomas…
-
EMA approval · 2025-09-09EMA Authorised: Revlimid (lenalidomide) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Revlimid (lenalidomide) for multiple indications including multiple myeloma, mantle cell lymphoma, …
-
CLINICAL_TRIALS trial_result · 2025-09-09Clinical Trial Update: Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]
Update on a Phase 1/2 study evaluating BGB-11417 monotherapy in participants with relapsed or refractory Mantle Cell Lymphoma; the trial is …
-
CLINICAL_TRIALS other · 2025-09-08Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) [Phase 1, Phase 2]
This clinical trial update indicates that Nemtabrutinib (MK-1026) is being studied for relapsed or refractory hematologic malignancies in a …
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 clinical trial update describes modified CD19/CD20 CAR-T cells for recurrent or refractory B-cell lymphoma or chronic lymphocytic …
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas [Phase 1]
Phase 1 feasibility trial evaluating the combination of tazemetostat with CAR T-cell therapy in B-cell lymphomas, including follicular lymph…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas [Phase 1]
Phase 1 clinical trial evaluating autologous CD22-directed CAR-T cells in patients with recurrent or refractory B-cell lymphomas, including …
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 study results are posted for a Bendamustine, Obinutuzumab, and Venetoclax regimen in patients with untreated Mantle Cell Lymphoma.
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]
This Clinical Trial Update describes a fourth-generation CD19/CD22 dual-targeting CAR T-cell therapy being evaluated in Phase 1/2 for highly…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]
Phase 1 clinical trial update on genetically engineered CAR T cells (EGFRt/19-28z/IL-12) for relapsed or refractory CD19+ hematologic malign…
-
CLINICAL_TRIALS trial_result · 2025-08-01Clinical Trial Update: A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) [Phase 2]
Phase 2 trial comparing BeEAM and BEAM high-dose chemotherapy regimens before autologous stem cell transplantation in lymphoma patients; the…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer [Phase 1]
A Phase 1 study of PEP07, a Checkpoint Kinase 1 (CHK1) inhibitor, is currently recruiting in patients with acute myeloid leukemia and mantle…
-
CLINICAL_TRIALS research · 2025-07-28Clinical Trial Update: A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies [Phase 1, Phase 2]
This document outlines a Phase I/II clinical trial of ALETA-001 for various B-cell lymphomas, with recruitment ongoing and sponsored by Canc…